Dermatology

Arcutis Appoints David Topper as Chief Financial Officer

Retrieved on: 
Wednesday, April 10, 2024
Stanford University, CFO, Morgan Stanley, Dermatology, J. P. Morgan, Duke University, General Atlantic, Equity capital markets, JPM, Organization

WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effective April 10, 2024.

Key Points: 
  • WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effective April 10, 2024.
  • Mr. Smither will remain at Arcutis through the end of April to ensure a smooth transition.
  • “We could not be more pleased to welcome David as chief financial officer at this transformational time,” said Frank Watanabe, president and CEO of Arcutis.
  • We wish him well as he transitions to non-operating roles.”
    “I am excited to join the amazingly strong Arcutis organization at this time,” said Mr. Topper.

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, April 10, 2024
FDA, Complaint, Dentist, Dermatology, Injury, Court, Confidentiality, Food and Drug Administration, Person

InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Cutera to Announce First Quarter Results on May 9, 2024

Retrieved on: 
Friday, April 26, 2024
Surgery, Medical Devices, Other Health, Health, Health Technology, Calendar, Dermatology, PIN

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024.

Key Points: 
  • Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024.
  • The Company’s management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m.
  • The call will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/ .
  • The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Transat CIC, Three Days to the Start for the Class40 IBSA

Retrieved on: 
Thursday, April 25, 2024
Pharmaceutical, Sailing, Health, Sports, Transat Jacques Vabre, Class40, Pain, Courage, BOAT, Inflammation, Panerai, Transat, Solitaire, IBSA, ARC, Safety, Disability, Partnership, Endocrinology, Dermatology, Maserati, Atlantic Ocean, Water, Quality, Risk, Figaro, Future, ULDB, Face, CHF, Route, Temperature, Gruppo TIM, Running, Philosophy, Reproductive medicine, Shipbuilding

Three days before the start, scheduled for 1:02 p.m. on Sunday, April 28, the third season of the project Sailing into the Future.

Key Points: 
  • Three days before the start, scheduled for 1:02 p.m. on Sunday, April 28, the third season of the project Sailing into the Future.
  • Together, sponsored by IBSA, gets underway with a test that is already set to become epic, due to the many difficulties to overcome.
  • “We are ready for this new undertaking of the Class40 IBSA,” declared Giorgio Pisani, Vice President IBSA Group and Leader of the project Sailing into the Future.
  • In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre.

AndHealth Partners with PrimaryOne Health to Address Health Inequities by Offering In-House Specialty Care

Retrieved on: 
Tuesday, April 23, 2024
General Health, Professional Services, Hospitals, Family, DEI (Diversity, Equity and Inclusion), Dental, Consumer, Health, Health Technology, Health Insurance, Telemedicine, Virtual Medicine, Other Health, Women, Human Resources, Pharmaceutical, Optical, Practice Management, Health equity, CHC, Rheumatology, Pediatrics, Partnership, Social, Community health center, Community, Patient, Neurology, Rheumatoid arthritis, Psoriasis, Headache, Movement, Face, Health system, Migraine, Sleep, Dermatology, Nursing

AndHealth announced today its partnership with PrimaryOne Health to bring in-house whole-person specialty care to the communities they serve.

Key Points: 
  • AndHealth announced today its partnership with PrimaryOne Health to bring in-house whole-person specialty care to the communities they serve.
  • PrimaryOne Health supports Franklin County and Pickaway County as the oldest and largest Community Health Center (CHC) in central Ohio.
  • Since 1997, PrimaryOne Health has delivered whole-person care to the medically underserved communities of central Ohio including primary care, OB/GYN, dental, vision, behavioral health, and pediatrics.
  • This comprehensive, whole-person approach to specialty care enables patients to have better health outcomes and receive care directly within their medical home.

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Retrieved on: 
Wednesday, April 24, 2024
Cosmetics, Lifestyle, Retail, Health, Consumer, Pharmaceutical, USD, Core, Corporation, FDA, American Academy, Prurigo nodularis, SWX, International, Social, Acne, Super Bowl, Aesthetics, Dermatology, Business ethics, Sustainalytics, Chinese New Year, Neuromodulation, Filler (animal food), Bowl game, IPO, Science, Patient, ESG, AAD, Atopic dermatitis, Growth, Corporate governance, SIX Swiss Exchange, Pharmaceutical industry

Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.

Key Points: 
  • Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.
  • Injectable Aesthetics net sales for the first quarter of 2024 were 511 million USD, with year-on-year growth of 19.3% on a constant currency basis.
  • Dermatological Skincare net sales for the first quarter of 2024 were 351 million USD, with year-on-year growth of 8.4% on a constant currency basis.
  • Therapeutic Dermatology net sales for the first quarter of 2024 were 209 million USD, with year-on-year growth of 4.1% on a constant currency basis.

Anne Arundel Dermatology Adds Intelligent Scheduling Capabilities to Improve Patient Experience

Retrieved on: 
Tuesday, April 23, 2024
Data Management, Health, Technology, Practice Management, Health Technology, Software, General Health, Dermatology, Partnership, Patient, Research, Pathology, Organization, Nursing

Anne Arundel Dermatology (AADerm), a leading provider of medical, surgical, pathology, research and aesthetic dermatological services, announced today that it will add new intelligent patient scheduling tools, expanding its existing partnership with Relatient , a leading patient scheduling platform.

Key Points: 
  • Anne Arundel Dermatology (AADerm), a leading provider of medical, surgical, pathology, research and aesthetic dermatological services, announced today that it will add new intelligent patient scheduling tools, expanding its existing partnership with Relatient , a leading patient scheduling platform.
  • We pride ourselves on attentiveness to both clinical and interpersonal details that enable us to deliver the best care,” said Vincent Bradley, CEO of Anne Arundel Dermatology.
  • This, paired with Relatient's proven track record in patient scheduling, made it a no-brainer to expand our work.
  • We’re thrilled to help Anne Arundel lead the way on these key initiatives.”

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Retrieved on: 
Monday, April 22, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Staphylococcus epidermidis, Protein, Skin, Abstract, LEKTI, Patient, Dermatology, Netherton syndrome, Vaccine

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.
  • ATR-12 has been engineered to deliver missing LEKTI protein when applied topically to Netherton syndrome patients.
  • The data in the abstracts released online today show that topical application of ATR-12 in preclinical models reduced produced reduced IL-36γ by 93% compared to skin extracts induced to overexpress IL-36γ.
  • Additionally, topical application of ATR-12 significantly reduced protease activity in skin samples compared to a Netherton syndrome model skin (p

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

Retrieved on: 
Thursday, April 18, 2024
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, Workforce, Sale, AlixPartners, Dermatology, Acquisition, Comment, Disclosure

Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company.

Key Points: 
  • Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company.
  • The Company is also implementing a restructuring plan to significantly reduce expenses associated with its current operations to preserve cash.
  • These restructuring actions will result in a workforce reduction of approximately 100 employees, or approximately 56% of DermTech’s workforce.
  • The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 in connection with these restructuring actions.

Global Dermocosmetic (Skin, Hair) Market Analysis Report 2024: Innovations in Bioengineering Transforming the Industry - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2024
Cosmetics, Retail, General Health, Health, Online, USD, Market, Supermarket, Sale, Dermatitis, Porter's five forces analysis, Epidemiology, Acne, SWOT, Particulates, Skin, AI, Genetic engineering, John Foster Dulles, Pharmacy, Life, Dermatology, Algorithm, Dehydration, Incidence, Patient, Hyperpigmentation, Psoriasis, Dermatologic Clinics, Rosacea, Child, Beauty, Biological engineering, Urbanization, Ageing, Fermentation, UV, Prevalence, Air pollution, Beauty salon

The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.

Key Points: 
  • The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.
  • This report provides a complete analysis for the historical period of 2020-2023, estimates of 2024 and the forecast period of 2025-2030.
  • The report presents the analysis of Dermocosmetic Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.